SCHEMBL3798568

SCHEMBL3798568

CC1CN(c2ccccc2Nc2ncnc3sccc23)CC(C)N1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
MKNK1 Q9BUB5 5/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
MAPK1 P28482 1/20 0.43
TNF P01375 1/20 0.42
NOD1 Q9Y239 1/20 0.42
EGFR P00533 1/20 0.41
FADS1 O60427 1/20 0.41
PIP4K2A P48426 1/20 0.41
PIP4K2C Q8TBX8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3802928 0.82 RAB9A (0.51) MEN1KMT2ARAB9ANPC1POLB
SCHEMBL3798041 0.81 LMNA (0.44) MEN1KMT2ARAB9APOLBMAPT
SCHEMBL3797489 0.81 RAB9A (0.50) MEN1KMT2ARAB9ANPC1POLB
SCHEMBL3796864 0.79 NPC1 (0.66) MEN1KMT2ARAB9ANPC1POLB
SCHEMBL3798672 0.78 NPC1 (0.41) MEN1KMT2ARAB9ANPC1POLB
SCHEMBL3794281 0.74 MEN1 (0.52) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9431935 0.73 KMT2A (0.54) MEN1KMT2ARAB9ANPC1MKNK1
SCHEMBL3799139 0.71 MEN1 (0.54) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3797107 0.70 RAB9A (0.60) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3801680 0.70 MEN1 (0.71) MEN1KMT2ARAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US claimed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP claimed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO claimed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP disclosed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, PDXK MEN1 1106/4885KMT2A 1016/4885RAB9A 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.